Trialect

+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

NOIP: Centers without Walls for mechanisms of neurodegeneration in Alzheimers disease-related dementias (ADRD)

National Institutes of Health

Note: This is a Forecasted Opportunity.

The National Institute of Neurological Disorders and Stroke (NINDS) is interested in supporting ambitious research projects to elucidate mechanisms of neurodegeneration in Alzheimer’s disease-related dementias (ADRD) organized as a “Center without Walls” consortium. NINDS Centers without Walls are collaborative research networks that bring together diverse expertise from different institutions to tackle complex neurological problems that are not tractable by individual research projects.

This program is considering using an activity code, such as the RM1, that enables interdisciplinary research consortia capable of identifying and characterizing novel ADRD mechanisms. Teams may include cross-disciplinary and cross-specialty expertise to address the complex co-pathologies, mixed etiologies, and disease heterogeneity in ADRD.

This program is anticipated to support teams that can combine multiple approaches, such as state-of-the-art technologies, disease-relevant models, clinical science, and human specimens, to investigate unique disease mechanisms and identify new therapeutic targets, biomarkers, and other factors influencing ADRD susceptibility, resilience, and pathology. One awardee team would serve as a coordinating center for all awardees to facilitate recurring meetings, data harmonization and sharing, cross-site communication, and support the implementation of inter-laboratory rigor and reproducibility plans.

This program is informed by key priorities from the ADRD Summit 2025, including embracing ADRD complexity and breaking down topic- and disease-based silos, and is intended to provide a mechanistic foundation for future translational and clinical ADRD research.

Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. Investigators with complementary expertise in ADRD mechanisms, clinical phenotypes, and advanced technologies are encouraged to contact agency staff listed below for additional information.

Estimated Post Date:

May 18, 2026

Estimated Application Due Date:

Oct 01, 2026

Specialties

Interdisciplinary

Medical - Basic Science

Medical - Translational

Medical

Medical - Clinical Science

Eligibility Requirements

Sponsor Details

Sponsor Institute/Organizations: National Institutes of Health

Sponsor Type: Government/Federal

Address: National Institutes of Health; 31 Center Drive; MSC 2220; Bethesda; MD 20892-2220; USA

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity